GNF362
中文名称 | GNF362 |
---|---|
中文同义词 | 化合物 T11446 |
英文名称 | GNF362 |
英文同义词 | GNF362;GNF362,GNF-362;Benzonitrile, 4-[4-[[(3R)-3-methyl-4-[5-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]methyl]-1H-pyrazol-3-yl]- |
CAS号 | 1003019-41-7 |
分子式 | C22H21F3N6 |
分子量 | 426.44 |
EINECS号 | |
相关类别 | |
Mol文件 | 1003019-41-7.mol |
结构式 | ![]() |
GNF362 性质
沸点 | 623.9±55.0 °C(Predicted) |
---|---|
密度 | 1.38±0.1 g/cm3(Predicted) |
储存条件 | Store at -20°C |
溶解度 | 二甲基亚砜:125 mg/mL(293.12 mM) |
酸度系数(pKa) | 13.04±0.50(Predicted) |
形态 | 固体 |
颜色 | 白色至米白色 |
GNF362 (0-10 mM) blocks Ins (1,3,4,5) P4 production, enhances antigen receptor-driven Ca 2+ responses and lead to apoptosis of activated T cells in an Itpkb-dependent manner in lymphocytes. GNF362 augments SOC responses following antigen receptor cross-linking, with an EC 50 of 12 nM in primary B or T lymphocytes.
GNF362 (orally administration; 6 or 20 mg/kg; twice daily; 21 days) shows minimal block in antibody production but shows significant inhibition of joint swelling at 6 mg/kg, reduces inflammatory cell infiltrate, joint damage, and proteoglycan loss at 20 mg/kg.
Animal Model: | A Lewis rat antigen-induced arthritis (rAIA) model |
Dosage: | 6 or 20 mg/kg |
Administration: | Orally administration; 6 or 20 mg/kg; twice daily; 21 days |
Result: | Reduced knee swelling in both the 20mg/kg and 6mg/kg treatment groups of GNF362 by 47% and 34%, respectively. |
安全信息
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2024/08/19 | HY-126750 | GNF362 | 1 mg | 1590元 | |
2024/08/19 | HY-126750 | GNF362 GNF362 | 1003019-41-7 | 10mM * 1mLin DMSO | 3280元 |